Treating haemophilia A with recombinant blood factors: a comparison
| Autor: | Natalya M. Ananyeva, Alexey V. Khrenov, Evgueni L. Saenko, Robert Summers, Andrey Sarafanov, Fred Darr |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
congenital
hereditary and neonatal diseases and abnormalities animal diseases Haemophilia A Hemophilia A Haemophilia law.invention Clinical Trials Phase II as Topic Animal proteins law hemic and lymphatic diseases Animals Humans Multicenter Studies as Topic Medicine Pharmacology (medical) Pharmacology Factor VIII business.industry Plasma derived General Medicine medicine.disease Recombinant Proteins Safety profile Clinical Trials Phase III as Topic Immunology Recombinant DNA business |
| Zdroj: | Expert Opinion on Pharmacotherapy. 5:1061-1070 |
| ISSN: | 1744-7666 1465-6566 |
| DOI: | 10.1517/14656566.5.5.1061 |
| Popis: | The mainstay in the treatment of haemophilia A is replacement therapy with repeated infusions of plasma-derived Factor VIII (FVIII) concentrates or recombinant FVIII products. While modern plasma-derived FVIII concentrates have an excellent safety profile, there is an inexorable shift towards the use of recombinant products, especially in affluent countries. Recombinant FVIII products have demonstrated excellent haemostatic efficacy and higher safety with regard to the transmission of blood-borne pathogens. The experience in haemophilia A treatment with five currently available recombinant FVIII products, including the first third-generation product, Advate®, which is completely free from human or animal proteins, is summarised. Some unresolved problems concerning the efficacy and assaying of recombinant factors and future perspectives of both recombinant and plasma-derived FVIII products in global haemophilia care, are also discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|